# VHB937 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vhb937

> The next catalyst for VHB937, sponsored by NOVARTIS AG (NVS), is its topline data readout, Sep to Dec 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | VHB937 |
| Codes | VHB937 |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications | [Alzheimer's Disease](https://sec-api.dev/indications/alzheimer-s-disease), [Amyotrophic Lateral Sclerosis (ALS)](https://sec-api.dev/indications/amyotrophic-lateral-sclerosis-als) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### June 23, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Amyotrophic Lateral Sclerosis (ALS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06643481 (A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-23 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06643481

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07094516 (A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-09-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT07094516

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07094516 (A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-09-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT07094516

## Same indication

- [COYA-302](https://sec-api.dev/pdufa/coya-302) (COYA)
- [Debamestrocel - msc-ntf (nurown)](https://sec-api.dev/pdufa/debamestrocel-msc-ntf-nurown) (BCLI)
- [GSK4527226](https://sec-api.dev/pdufa/gsk4527226) (GSK)
- [Karxt](https://sec-api.dev/pdufa/karxt) (BMY)
- [NBI-1117567](https://sec-api.dev/pdufa/nbi-1117567) (NBIX)
- [Remternetug](https://sec-api.dev/pdufa/remternetug) (LLY)
- [Xanomeline/trospium chloride](https://sec-api.dev/pdufa/xanomeline-trospium) (BMY)

Calendar months: [September 2028](https://sec-api.dev/fda-calendar/2028-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vhb937.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VHB937 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vhb937

```bibtex
@misc{secapidev_pdufa_vhb937_20261116,
  title        = {VHB937 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vhb937}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vhb937_20261116","title":"VHB937 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vhb937","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
